Literature DB >> 10659757

A Monte Carlo dosimetry-based evaluation of the 7Li(p,n)7Be reaction near threshold for accelerator boron neutron capture therapy.

C L Lee1, X L Zhou, R J Kudchadker, F Harmon, Y D Harker.   

Abstract

Advanced methods of boron neutron capture therapy (BNCT) use an epithermal neutron beam in conjunction with tumor-targeting boron compounds for irradiation of glioblastomas and metastatic melanomas. A common neutron-producing reaction considered for accelerator-based BNCT is 7Li(p,n)7Be, whose cross section increases very rapidly within several tens of keV of the reaction threshold at 1.88 MeV. Operation in the proton energy region near threshold will have an appreciable thick target neutron yield, but the neutrons produced will have relatively low energies that require little moderation to reach the epithermal range desirable for BNCT. Because of its relatively low projected accelerator cost and the portability of the neutron source/target assembly, BNCT based on the near-threshold technique is considered an attractive candidate for widespread hospital use. A systematic Monte Carlo N-Particle (MCNP) investigation of the dosimetric properties of near-threshold neutron beams has been performed. Results of these studies indicate that accelerator proton energies between 1.93 and 1.99 MeV, using 5 cm of H2O moderator followed by thin 6Li and Pb shields, can provide therapeutically useful beams with treatment times less than one hour and accelerator currents less than 5 mA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10659757     DOI: 10.1118/1.598884

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

Review 1.  Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

Authors:  Thomas E Blue; Jacquelyn C Yanch
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

2.  An accelerator-based neutron microbeam system for studies of radiation effects.

Authors:  Yanping Xu; Gerhard Randers-Pehrson; Stephen A Marino; Alan W Bigelow; Mark S Akselrod; Jeff G Sykora; David J Brenner
Journal:  Radiat Prot Dosimetry       Date:  2010-12-03       Impact factor: 0.972

3.  Application of an ultraminiature thermal neutron monitor for irradiation field study of accelerator-based neutron capture therapy.

Authors:  Masayori Ishikawa; Kenichi Tanaka; Satrou Endo; Masaharu Hoshi
Journal:  J Radiat Res       Date:  2015-01-14       Impact factor: 2.724

4.  Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system.

Authors:  Satoshi Nakamura; Shoji Imamichi; Kazuyoshi Masumoto; Masashi Ito; Akihisa Wakita; Hiroyuki Okamoto; Shie Nishioka; Kotaro Iijima; Kazuma Kobayashi; Yoshihisa Abe; Hiroshi Igaki; Kazuyoshi Kurita; Teiji Nishio; Mitsuko Masutani; Jun Itami
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2017       Impact factor: 3.493

5.  Optimized beam shaping assembly for a 2.1-MeV proton-accelerator-based neutron source for boron neutron capture therapy.

Authors:  Pablo Torres-Sánchez; Ignacio Porras; Nataliya Ramos-Chernenko; Fernando Arias de Saavedra; Javier Praena
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

6.  A fast Monte Carlo code for proton transport in radiation therapy based on MCNPX.

Authors:  Keyvan Jabbari; Jan Seuntjens
Journal:  J Med Phys       Date:  2014-07

7.  Characterization of the relationship between neutron production and thermal load on a target material in an accelerator-based boron neutron capture therapy system employing a solid-state Li target.

Authors:  Satoshi Nakamura; Hiroshi Igaki; Masashi Ito; Hiroyuki Okamoto; Shie Nishioka; Kotaro Iijima; Hiroki Nakayama; Mihiro Takemori; Shoji Imamichi; Tairo Kashihara; Kana Takahashi; Koji Inaba; Kae Okuma; Naoya Murakami; Yoshihisa Abe; Yuko Nakayama; Mitsuko Masutani; Teiji Nishio; Jun Itami
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.